We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Immunohistochemistry as Effective as DNA Hybridization for Detecting ALK Rearrangement in Lung Cancer Patients

By LabMedica International staff writers
Posted on 08 Jul 2013
A team of Chinese researchers demonstrated that immunohistochemistry (IHC) provided a reliable and cost-effective diagnostic approach in routine pathologic laboratories for the identification of patients with non-small-cell lung cancer (NSCLC), in particular adenocarcinomas (ADCs), suitable for ALK-targeted therapy.

The ALK gene can be oncogenic in three ways: by forming a fusion gene with any of several other genes, by gaining additional gene copies, or with mutations of the actual DNA code for the gene itself. More...
The EML4-ALK (echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase) fusion gene is responsible for approximately 3%–5% of cases of NSCLC. The standard tests used to detect this gene in tumor samples is fluorescence in situ hybridization (FISH), and Reverse Transcriptase-PCR (RT-PCR). The FISH technique utilizes a DNA probe labeled with a fluorescent dye that is hybridized with target DNA, usually chromosome preparations on a microscopic slide. It is used to precisely map genes to a specific region of a chromosome in prepared karyotype, or can enumerate chromosomes, or can detect chromosomal deletions, translocations, or gene amplifications in cancer cells.

As IHC is a less complex and less costly technology than FISH, investigators at the Chinese University of Hong Kong SAR (China) evaluated its practical usefulness for detection of ALK rearrangement in NSCLC ADCs. They tested 373 lung ADCs for ALK rearrangement by IHC and FISH. Multiplex RT-PCR was performed to confirm the fusion variants.

Results showed that 22 of 373 lung ADCs (5.9%) were positive for ALK immunoreactivity. ALK-positive tumor cells demonstrated strong and diffused granular staining in the cytoplasm. All the ALK IHC-positive cases were confirmed to harbor ALK rearrangement, by either FISH, or RT-PCR. Two cases that were positive for ALK protein expression by IHC, but negative by FISH were shown to harbor EML4-ALK variant 1 by RT-PCR. None of the ALK IHC-negative cases was FISH-positive.

These results allowed the investigators to conclude that, "IHC can effectively detect ALK rearrangement in lung cancer. It might provide a reliable and cost-effective diagnostic approach in routine pathologic laboratories for the identification of suitable candidates for ALK-targeted therapy."

The study was published in the July 2013 issue of the Journal of Thoracic Oncology.

Related Links:
Chinese University of Hong Kong



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
HPV Test
Allplex HPV28 Detection
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Elevated creatinine levels do not necessarily indicate impaired kidney function: pre-treatment cystatin C measurement is key to assessment (Image Credit: Data panels adapted from Watanabe H, et al. Clin Pharmacol Ther (2026). All icons were obtained from bioicons.com and modified.)

Cystatin C Testing Helps Distinguish Abemaciclib Effect from Kidney Injury

Kidney function monitoring in breast cancer care often relies on serum creatinine, a routine blood marker used to estimate renal function. However, creatinine increases in patients receiving abemaciclib... Read more

Molecular Diagnostics

view channel
Image: These images show breast tumors in a new preclinical model developed by Garvan researchers. The cells carry a fluorescent sensor that lights up blue/green when CDK1—the protein \'engine\' cells need to divide—is switched on. Using it, the team watched CDK1 activity rise as tumors became invasive and stay high in tumors that kept growing despite treatment. (Image Credit: Dr. Max Nobis / Garvan Institute)

Study Finds Potential Marker of Targeted Drug Resistance in Breast Cancer

Estrogen receptor-positive breast cancer is the most common breast cancer subtype and is driven by estrogen. Many patients are treated with CDK4/6 inhibitors alongside hormone therapy, but these drugs... Read more

Hematology

view channel
Image: Mayo Clinic researchers used genetic data from nearly 50,000 participants to identify sickle cell and beta-thalassemia carrier traits, highlighting how population-scale testing can complement existing screening (Image Credit: Adobe Stock)

Genetic Testing Offers Opportunities for Earlier Blood Disorder Carrier Identification

Inherited hemoglobin disorders can affect oxygen transport, yet individuals who carry only a trait may remain unaware of their status. People with sickle cell trait or beta-thalassemia trait often have... Read more

Microbiology

view channel
Image: The test uses serum or plasma from patients with suspected acute infection and symptoms lasting fewer than seven days and generates a score indicating the likelihood of bacterial infection. (Image Credit: Shutterstock)

Rapid Host-Response Assay Gains FDA Clearance to Help Distinguish Bacterial and Viral Infections

Bacterial and viral infections often cause similar symptoms, making early differentiation difficult in emergency and urgent care settings. Clinicians may need to begin treatment before traditional diagnostic... Read more

Industry

view channel
Image: The ExaccType ESR1 dPCR Kit uses digital PCR technology to detect key ESR1 mutations associated with acquired resistance to endocrine therapy. (Photo courtesy of  BIOTYPE)

Collaboration Expands Access to Tests for Cancer Treatment Resistance and Toxicity Risk

Precision medicine in oncology relies on molecular testing to identify biomarkers that can help guide treatment decisions. In hormone receptor-positive, HER2-negative metastatic breast cancer, ESR1 mutations... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.